Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow Jrheum on BlueSky
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
EditorialEditorial

Send Us Your Best

EARL SILVERMAN
The Journal of Rheumatology January 2013, 40 (1) 3; DOI: https://doi.org/10.3899/jrheum.121371
EARL SILVERMAN
Journal of Rheumatology, Professor of Pediatrics, Ho Family Chair in Autoimmune Diseases, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
MD, FRCPC
Roles: Editor-in-Chief
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: esilverman@jrheum.com earl.silverman@sickkids.ca
  • Article
  • Info & Metrics
  • References
  • PDF
PreviousNext
Loading

This is my first editorial as the new editor of The Journal of Rheumatology. It is an honor to be only the third editor of one of the first journals in the field of Rheumatology. I am following the founding editor, Dr. Metro Ogryzlo, and the retiring editor, Dr. Duncan Gordon. It is also fitting that The Journal of Rheumatology, which has been a leader in rheumatology and a source of knowledge and investigation in all fields of this subspecialty, including pediatric rheumatology, should now have a pediatric rheumatologist as the editor.

When it became apparent that The Journal was looking for a new editor, and when I considered applying for the position, I thought about how to build on the current strengths of The Journal and look to the future. This becomes particularly important in the 21st century with the explosion of information and technology in many new journals, both in print and online. As information technologies advance and with the world going increasingly to online formats, new challenges and opportunities arise. The challenges include how to stay current and relevant with ever-changing technologies, including blogs and Twitter. However, I see these technologies as opportunities to build on the current strengths of The Journal and to expand its reach. The recent acquisition of The Journal by the Canadian Rheumatology Association has given us the opportunity to reassess all aspects of publication, including ways to make The Journal a more international journal. The first change has been to use teleconferencing to expand the editorial committee to include members outside of Toronto in particular and Canada in general. In the future I hope to increase the international flavor of the editorial board even further.

I also see new opportunities to focus and expand our current forte, which is clinical rheumatology. You will find in this edition a review article entitled “The Risky Business of Studying Prognosis”1. This is the first of what I hope will be many articles that will allow The Journal’s readers to keep up with ever-expanding new ways to examine medical literature. In this particular issue, we will be using the expertise of clinical epidemiologists to explore how to best use the tremendous amount of information available through cohort studies. This is a particularly daunting challenge as these data are obtained from real-life cohorts, not patients following a strict protocol. However, these cohorts, although rich in clinically relevant data, have many problems including missing data and irregular visits. We will continue to publish articles on how to best examine literature in order to obtain the information relevant to the practice of rheumatology. Other new features will explore recent insights into the pathophysiology of rheumatic diseases; the clinical relevance of genome-wide association studies; and making sense of epigenetics, proteomics, and bioinformatics and whatever new technologies will be coming to us in the future. I feel that with the many technologies to study disease it is difficult to keep up with what this information truly means and how, or if, it is currently important to clinical rheumatology. I look forward to feedback from the readership on their interest in and suggestions for future topics.

An important challenge is how to best transmit all these topics, whether it is via the written page or electronically. The advantages of online access to information include ease of access, rapidity of access, and portability. However, this too presents us with new considerations, not the least of which is to maintain financial viability.

I want to thank The Journal’s Board of Directors for their confidence — and the Canadian Rheumatology Association for its blessing — in selecting me as the new editor to follow in the footsteps of some of the giants of Rheumatology — Drs. Ogryzlo and Gordon. I see this as an opportunity to enhance the outstanding reputation of The Journal and guide it through the challenges of the digital age. I want to end by adapting the motto that Duncan Gordon had for The Journal, which was “Send us some of your best.” I want to change it to “Send us your best.”

REFERENCE

  1. 1.↵
    1. Lim L,
    2. Feldman B
    . The risky business of studying prognosis. J Rheumatol 2013;40:9–15.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 40, Issue 1
1 Jan 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Send Us Your Best
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Send Us Your Best
EARL SILVERMAN
The Journal of Rheumatology Jan 2013, 40 (1) 3; DOI: 10.3899/jrheum.121371

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Send Us Your Best
EARL SILVERMAN
The Journal of Rheumatology Jan 2013, 40 (1) 3; DOI: 10.3899/jrheum.121371
del.icio.us logo Twitter logo Facebook logo  logo Mendeley logo
  • Tweet Widget
  •  logo
Bookmark this article

Jump to section

  • Article
    • REFERENCE
  • Info & Metrics
  • References
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The Nuances of Shared Autoimmunity and the Singularity of Mixed Connective Tissue Disease
  • Does Prior Authorization for Tocilizumab Lead to Unacceptable Treatment Delays in Giant Cell Arteritis?
  • Practical Issues Relating to the Use of Antifibrotic Therapy in Patients With Interstitial Lung Disease and Rheumatoid Arthritis
Show more Editorial

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2025 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire